** Paradigm M. erhält FDA-Verkaufserlaubnis **

" We are extremely pleased to add Fred Geiger to our management team," noted Paradigm Medical's Chief Executive Officer, John Y. Yoon. " He brings a broad array of disciplines, including engineering, product management, and information technology. Fred will be instrumental in retooling Paradigm Medical's product line, as we have done with the P60."

Paradigm Medical Industries, Inc., currently develops, manufactures and markets surgical and diagnostic high-tech, proprietary equipment and consumable products for the medical industry. The Company's corporate headquarters are located at 2355 South 1070 West, Salt Lake City, Utah 84119. Call (801) 977-8970 or visit us at www.paradigm-medical.com.

This press release contains statements that, if not verifiable historic fact, may be viewed as forward-looking statements that could predict future events or outcomes with respect to Paradigm and its business. The predictions embodied in these statements will involve risk and uncertainties and, accordingly, actual results may differ significantly from the results discussed or implied in such forward-looking statements.

Was ist mit blos mit Dir aufeinmal los?img.wallstreet-online.de/smilies/frown.gif" style="max-width:560px" border=0>

Also ich werde jetzt nicht zum aussteigen trommeln!img.wallstreet-online.de/smilies/cry.gif" style="max-width:560px" border=0>
Die ganze Firma wird bald komplett neu bewertet. Man muß sich nur mal die weltweiten Absatzmöglichkeiten vor Augen führen und Paradigm hat schon mal weltweit agiert und die Vertriebsschienen sind immer noch vorhanden. Das P60 ist die Zukunft pur und wird entsprechend auch den Umsatz erheblich steigern!

Mein Kursziel liegt bei einer Marktkapitalisierung von 10 Mio Dollar und ob es heute ca. 53 Mio Aktien oder morgen ein paar mehr gibt läßt sich jederzeit per Mathematik den Kurswert pro Aktie ausrechnen. Das erste Kurszeil sind die 0,05 Dollar und wenn der Newsflow stimmt dann dürften die 0,10 Dollar in 6 Monaten auch zu ereichen sein.

Wir wissen ja wo der Kurs von Paradigm herkommt
charts.edgar-online.com/ext/...ll?2-6-9-0-0-548-03NA000000PMED alt="** Paradigm M. erhält FDA-Verkaufserlaubnis ** 2400898" title="" rel="nofollow" src="charts.edgar-online.com/ext/...l?2-6-9-0-0-548-03NA000000PMED" style="max-width:560px" border=0>

aber wir sehen auch den return!

charting.nasdaq.com/ext/...14-0-0-512-03NA000000PMED-&SF:4|5-WD=484-HT=395- alt="** Paradigm M. erhält FDA-Verkaufserlaubnis ** 2400898" title="" rel="nofollow" src="charting.nasdaq.com/ext/...14-0-0-512-03NA000000PMED-&SF:4|5-WD=484-HT=395-" style="max-width:560px" border=0>

Man kann hier ein wenig Geld verlieren, aber man kann hier aber auch mächtig was verdienen!img.wallstreet-online.de/smilies/rolleyes.gif" style="max-width:560px" border=0>

da hat ja wieder jemand ein gutes näschen gehabt und wusste wann er raus muss.. :)

Kurz vor Schluß noch mal nachgelegt,
So kanns morgen weitergehen

Die Chancen stehen jeden 50:50 das die Aktie steigen oder fallen!


Wer einen etwas längeren Atem hat für den stehen die Chancen um einiges besser das der steigende Trend hält!

Form 8-K for PARADIGM MEDICAL INDUSTRIES INC

---

1-Mar-2006

Other Events, Financial Statements and Exhibits

ITEM 8.01 Other Events

On February 28, 2006, Paradigm Medical Industries, Inc. (the "Company") completed financing involving the sale of $1,500,000 in secured convertible notes. The notes are to be purchased in three traunches of $500,000 each. The Company received the first traunche upon the signing of the definitive investment agreements on February 28, 2006. The Company will receive the second traunche upon the filing of a registration statement with the Securities and Exchange Commission and the third traunche upon the effectiveness of the registration statement. The financing was obtained through The NIR Group of Rosalyn, New York and Laidlaw & Co. (UK) Ltd. of New York City.

Under the terms of the notes, the unpaid principal balance of notes, together with any accrued interest thereon, are due and payable three years after the date of issuance. The unpaid principal balance on the notes that were purchased on February 28, 2006 is due on February 28, 2009. Interest is payable on the notes at 8% per annum, payable quarterly in cash, with six months of interest payable up front. However, the interest rate resets to zero percent for any month in which the stock price is greater than 125% of the initial market price, or $.0275, for each trading date during that month.

The notes are secured by the Company's assets, including the Company's inventory, accounts receivable and intellectual property. The notes are also convertible. The Purchasers have the right to convert their notes at any time into shares of the Company's common stock. The conversion price of the notes is equal to the lesser of (i) $.02 and (ii) the average of the lowest intra-day trading prices during the 20 trading days immediately prior to the conversion date discounted by 40%. However, in no event are the Purchasers allowed to convert any portion of their notes in excess of that portion of the notes upon conversion of which the sum of the number of shares beneficially owned by the Purchasers and the number of shares issuable upon conversion of the portion of the notes with respect to which such determination is being made, would result in beneficial ownership by the Purchasers of more than 4.99% of the Company's outstanding common shares.

The Company has a call option under the terms of the notes. The call option provides the Company with the right to prepay all of the outstanding notes at any time, provided there is no event of default by the Company and the Company's stock is trading at or below $.10 per share. An event of default includes the failure by the Company to pay the principal or interest on the notes when due or to timely file a registration statement as required by the Company or obtain effectiveness with the Securities and Exchange Commission of the registration statement. Prepayment of the notes is to be made in cash equal to either (i) 125% of the outstanding principal and accrued interest for prepayments occurring within 30 days following the issue date of the notes; (ii) 130% of the outstanding principal and accrued interest for prepayments occurring between 31 and 60 days following the issue date of the notes; and (iii) 145% of the outstanding principal and accrued interest for prepayments occurring after the 60th day following the issue date of the notes.

The Company's right to repay the notes is exercisable on not less than ten trading days prior written notice to the Purchasers. For notice purposes, a trading day is any day on which the Company's common stock is traded for any period on the OTC Bulletin Board. Notwithstanding the notice of prepayment, the Purchasers have the right at all times to convert all or any portion of the notes prior to payment of the prepayment amount.

The Company also has a partial call option under the terms of the notes in any month in which the current price of its common stock is below the initial market price of $.02. Under the terms of the partial call option, the Company has the right to pay the outstanding principal amount of the notes plus one-month's interest for that month, which will stay any conversions of the notes by the Purchasers for that month. The principal amount of the notes to be repaid is determined by dividing the then outstanding principal amount of the notes by the maturity of the notes in months, or 36.

As further consideration to the Purchasers of the notes, the Company is required to issue warrants to the Purchaser to acquire an aggregate of 12,000,000 shares of the Company's common stock at an exercise price of $.10 per share. The warrants will have a five year term from the date of issuance, with cashless exercise permitted in the event there is not an effective registration statement registering the warrants. The Company is required to have authorized, and reserved for the purpose of issuance, a sufficient number of shares of its common stock to provide for the full conversion or exercise of the outstanding notes and warrants and the issuance of its common shares in connection therewith (based on the conversion price of the notes and exercise price of the warrants in effect from time to time) and as otherwise required by the notes.

The Company is required to register the shares of its common stock issuable upon the conversion of the notes and the exercise of the warrants. The registration statement must be filed with the SEC within 60 days of the February 28, 2006 closing date and the effectiveness of the registration is to be within 135 days of such closing date. Penalties of 2% of the outstanding principal balance of the notes plus accrued interest are to be applied for each month the registration is not effective within the required time. The penalty may be paid in cash or stock at the option of the Company.

The Company intends to use the proceeds from the financing for purchase of inventory, sales and marketing, and working capital.

ITEM 9.01 Financial Statements and Exhibits

(c)    Exhibits          10.1        Securities  Purchase Agreement with AJW Partners,  LLC, AJW                     Offshore,   Ltd.,  AJW  Qualified  Partners,  LLC  and  New                     Millennium Capital Partners II, LLP (the "Purchasers")         10.2        Form of Callable Secured  Convertible Note with each of the                     Purchasers         10.3        Form of Stock Purchase Warrant with each of the Purchasers         10.4        Security Agreement with the Purchasers         10.5        Intellectual   Property   Security   Agreement   with   the                     Purchasers         10.6        Registration Statement with the Purchasers

liest!


Auf jeden Fall kommt es zu einer Kapitalerhöhung und die neuen Aktien werden zum Teil weit über den jetzigen Marktpreis liegen! Es könnte sogar passieren das mit 0,10 Dollar neue Aktien gekauft werden!

Diese wichtige Nachricht kam kurz vor dem Börsenschluß in Amerika heraus.  Der  Börsenkurs hat daraufhin sofort angezogen.  

 

Ich will hier nicht pushen, aber es könnte durchaus passieren das es in kürze zu einer Kursexplosion kommen könnte! Bei W : O werde ich heute Abend in meinen eigenen Thread weiters darauf eingehen  wo ich schon Kurse von 0,10 Dollar in den nächsten 6 Monaten vorausgesagt habe. Ich bin der Meinung das hier was größeres entstehen kann und habe selber gut in diese Aktien eingekauft.

 

Ich will mich nicht ständig wiederholen, aber an der Berichtsfront zu Paradigm nimmt die Zahl der Repote (Analysen) weiter zu!

 

Research Reports Get Research Reports for:

RECENT REPORTS Released Contributor Author Title Pages Price 28-Feb-2006 Reuters Investment Profile N/A Paradigm Medical Industries, Inc.: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis. 11 $20 27-Feb-2006 Pechala's Reports Lubomir Pechala PARADIGM MEDICAL INDUSTRIES INC (PMED=US) 2-weeks forecast 1 $10 27-Feb-2006 Pechala's Reports Frantisek Pechala PARADIGM MEDICAL INDUSTRIES INC (PMED=US) 12-months forecast 1 $15 27-Feb-2006 Wright Reports N/A A textual analysis of Paradigm Medical Industries, Inc.'s financial statements, including company description and recent stock performance, versus PharmaNetics, Inc., International Isotopes Inc and Hemosense, Inc.. 0 $25 27-Feb-2006 ValuEngine, Inc. N/A ValuEngine Industry Report for HOSPITAL SUPPLIES 18 $49

 

 

 

 

Press Release Source: Paradigm Medical Industries, Inc.


Paradigm Medical Completes $1.5-Million Financing
Wednesday March 1, 3:31 pm ET


SALT LAKE CITY--(BUSINESS WIRE)--March 1, 2006--Paradigm Medical Industries, Inc. (OTCBB: PMED.OB/PMEDW.OB) today announced it has completed the sale of $1.5 million in secured convertible notes, through Laidlaw & Co. (UK) of New York City, and an institutional investor. The notes are to purchased by the investors in three traunches of $500,000 each. Paradigm Medical received the first traunche upon signing definitive investment agreements on February 28, 2006. The Company will receive the second traunche upon the filing of a registration statement with the Securities and Exchange Commission and the third traunche upon the effectiveness of the registration.
ADVERTISEMENT


"Additional capital is needed at this point to provide the Company will adequate funds to expand global sales and marketing programs, especially for the P60 Ultrasound BioMicroscope," said Paradigm Medical's Chief Executive Officer, Raymond P.L. Cannefax. "Moreover, we will now have adequate funds to purchase additional inventory to satisfy expected strong customer demand for all of our products."

The notes are due three years after issuance and are secured by Paradigm Medical's assets, including inventory, accounts payable and intellectual property. The notes are convertible into shares of the Company's common stock at anytime during their term. The conversion price is equal to the lesser of (a) $0.02 per share or (b) the average of the lowest intra-day trading prices during the 20 trading days immediately prior to the conversion date discounted by 40%.

Interest on the notes is payable at 8% per year, payable quarterly in cash, with six-months of interest payable up front. The notes are callable, with prepayment allowed at any time that the price of Paradigm Medical's stock is $0.10 per share or less.

In addition, Paradigm Medical is required to issue warrants to the investors to acquire an aggregate of 12 million shares of the Company's common stock, at an exercise price of $0.10 per share. The warrants will have a five-year term from the date of issuance, with cashless exercise permitted in the event there is not an effective registration statement registering the warrants.

Paradigm Medical is required to register the shares of its common stock issuable upon the conversion of the notes and the exercise of the warrants. The registration statement must be filed with the SEC within 60 days of the February 28, 2006 closing date and the effectiveness of the registration is to be within 135 days of such closing date.

Paradigm Medical Industries, Inc., currently develops, manufactures and markets high-tech, proprietary diagnostic equipment and consumable products for the medical industry. The Company's corporate offices are located at 2355 South 1070 West, Salt Lake City, Utah 84119. Call (801) 977-8970 or visit us at www.paradigm-medical.com.

This press release contains statements that, if not verifiable historic fact, may be viewed as forward-looking statements that could predict future events or outcomes with respect to Paradigm and its business. The predictions embodied in these statements will involve risk and uncertainties and, accordingly, actual results may differ significantly from the results discussed or implied in such forward-looking statements.



Contact:
Paradigm Medical Industries, Inc.
Raymond P.L. Cannefax, CEO, 801-977-8970

--------------------------------------------------
Source: Paradigm Medical Industries, Inc.

TUT SICH HEUTE GARNICHTS ODER????????????????????????????????

Das könnten bis zum Schluss über 50 Mio. werden. Und ein schönes Plus bis jetzt auch. Wenn die über 0,020 schliessen, ist morgen mit einen Run auf 0,030-0,040 zu rechnen. Bin gespannt ob nach diesen Umsätzen News folgen. Mich würde es jedenfalls nicht wundern.
mfg
S.H.

Nachdem gestern 50.000.000 Stück gehandelt wurden, und das bei steigenden Kursen, erwarte ich mir heute das fallen der 0,025 USD Marke. Nachhaltig würde dies den Weg auf 0,040 USD öffnen. News mit Aufträgen für das neue Produkt P60 werden erwartet. Dann kann es auf über 10 Cent gehen. Also Spannung ist garantiert.

mfg
S.H.

bi di bi dibbi...

wollte euch bis zum Start nur etwas die Zeit vertreiben...

Research Reports Get Research Reports for:

RECENT REPORTS Released Contributor Author Title Pages Price 4-Apr-2006 Reuters Investment Profile N/A Paradigm Medical Industries, Inc.: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis. 11 $20 3-Apr-2006 Pechala's Reports Lubomir Pechala PARADIGM MEDICAL INDUSTRIES INC (PMED=US) 2-weeks forecast 1 $10 3-Apr-2006 ValuEngine, Inc. N/A ValuEngine Summary Report for PMED 11 $9 3-Apr-2006 ValuEngine, Inc. N/A ValuEngine Industry Report for HOSPITAL SUPPLIES 18 $49 2-Apr-2006 Wright Reports N/A A textual analysis of Paradigm Medical Industries, Inc.'s financial statements, including company description and recent stock performance, versus PharmaNetics, Inc., International Isotopes Inc and Hemosense, Inc.. 0 $25 27-Feb-2006 Pechala's Reports Frantisek Pechala PARADIGM MEDICAL INDUSTRIES INC (PMED=US) 12-months forecast 1 $15

 

 

Dann kann es nicht mehr weit sein bis zum Startschuß!

Wenn alle Investoren ihre Stückzahlen haben geht es sowie so aufwärts. Es ist schon schön zu lesen wenn eine Firma mit einer Marktkapitalisierung von gerademal 0,75 Mio. Dollar  soviel Beachtung findet.  

nachzulesen bei yahoo

warum gehts immer weiter runter, umgerechnet nur mehr 0,008 Euro wert. Gibts Gründe ? Ich bin noch voll dabei und erwarte mir posetives, wissen andere mehr ?

mfg
S.H.

BUYINS.NET: PMED, SYNI Have Also Been Added To Naked Short List Today

Wednesday, April 19, 2006 09:28 ET

Apr 19, 2006 (M2 PRESSWIRE via COMTEX) -- www.buyins.net, announced today that these select companies have been added to the NASDAQ, AMEX and NYSE naked short threshold list: Paradigm Medical Industries, Inc. (OTCBB: PMED), Syngas International Corp: (OTCBB: SYNI). For a complete list of companies on the naked short list please visit our web site. To find the SqueezeTrigger Price before a short squeeze starts in any stock, go to www.buyins.net.

Paradigm Medical Industries, Inc. (OTCBB: PMED) engages in the development and marketing of diagnostic equipment for the ophthalmic market. Its product families of topographers, autoperimeters, and ultrasonic biomicroscopes combined with its Blood Flow Analyzer help the eye care professionals community diagnose and treat disorders of the eye, such as glaucoma, cataracts, and age-related macular degeneration. Its products include LD400, a voice-based, affordable, computer autoperimeter capable of threshold, fast threshold, and suprathreshold testing; CT200E, a computer-based corneal topographer with output for contact lens fitting, as well as pre and post refractive surgical measurements; Ocular Blood Flow Analyzer, a tonometer designed to measure intraocular pressure and sensitive enough to detect pulsatile blood flow; P37 A-B Scan, an ultrasonic A and B Scan for biometry and imaging of the retina; P40, an ultrasonic biomicroscope; P45, an ultrasonic biomicroscope with A and B Scan capabilities in addition to 35 MHz; and P60, an ultrasonic biomicroscope with sulcus-to-sulcus imaging and self-contained water path probe. It markets its products through direct sales representatives, independent sales representatives, and ophthalmic product distributors in the United States, as well as internationally through a network of dealers. The company was founded by Thomas F. Motter and Robert W. Millar in 1989 and is headquartered in Salt Lake City, Utah. With 52.96 million shares outstanding and an undisclosed short position, there is a failure to deliver in shares of PMED.

Syngas International Corp: (OTCBB: SYNI) through its subsidiary, Syngas Energy Corp., is an emerging leader in the development and marketing of low-cost alternate fuels worldwide. We believe our superior technology will catapult our company into a GREEN POWERHOUSE. With energy prices at high levels and the global focus moving rapidly towards addressing pollution, the need for sustainable, zero emission energy is vital. Our technology is based on clean renewable energy. We foresee our company poised to benefit from global trends. With 38.69 million shares outstanding and an undisclosed short position, there is a failure to deliver in shares of SYNI.

About BUYINS.NET

WWW.BUYINS.NET is a service designed to help bonafide shareholders of publicly traded US companies fight naked short selling. Naked short selling is the illegal act of short selling a stock when no affirmative determination has been made to locate shares of the stock to hypothecate in connection with the short sale. Buyins.net has built a proprietary database that uses Threshold list feeds from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the naked short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted and naked shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short and naked short trades.

-- The Company has consolidated its warehouse, production, and office facility into a more efficient and cost-effective space.



-- International distributor agreements are being reviewed and new distributors are eager to market Paradigm Medical's products in countries where there has been limited or no product distribution in the recent past.



-- The Company is exploring collaborations with leading global firms that have ultrasound research and development and production capabilities, to help develop new products that will be marketed globally by Paradigm Medical. Several of these products were well received at the AAO Conference held in March 2006.



-- Paradigm Medical is evaluating additional end-use market opportunities for its ultrasound products in ophthalmology."



"We are placing even greater emphasis on reducing our operating expenses and maintaining adequate inventory to meet expected demand four our products," Mr. Cannefax added. "The Company has adopted the slogan 'Continuous Improvements,' and is doing exactly that--continuously improving every aspect of our operations as well as our products."

Paradigm Medical Industries, Inc., currently develops, manufactures and markets high-tech, proprietary diagnostic equipment and consumable products for the medical industry. The Company's corporate offices are located at 2355 South 1070 West, Salt Lake City, Utah 84119. Call (801) 977-8970 or visit us at www.paradigm-medical.com.

This press release contains statements that, if not verifiable historic fact, may be viewed as forward-looking statements that could predict future events and outcomes with respect to Paradigm and its business. The predictions embodied in these statements will involve risk and uncertainties and, accordingly, actual results may differ significantly from the results discussed or implied in such forward-looking statements.

Paradigm Medical Industries, Inc. (OTCBB:  Berichtete Einkommen PMED.OB/PMEDW.OB vor) für das Jahr beendet Dezember 31, 2005 zeigten eine Abnahme von $900.000, verglichen mit der Jahr Periode.  Die Firma merkte, daß der Tropfen des Einkommens dem unerwarteten verzögert erfahrenes groß zuzuschreibend ist, wenn er den Ultraschall BioMicroscope (UMB), das P60 des folgenden Erzeugung ausstößt.  "letztes Jahr war ein vorübergehendes für die Firma.  Unsere Erwartungen waren grösser als was wir in der LageWAREN, zu erzielen, "sagten medizinischen Präsidenten des Paradigmas und Generaldirektor, Raymond Cannefax.  "nichtsdestoweniger, gab es eine Anzahl von vorteilhaften Entwicklungen, die erwartet werden, um Frucht 2006 und jenseits, vornehmlich die anhaltende Annahme unseres zukünftigen P60 UBM und die Einleitung unserer neu entworfenen Ultraschallproduktserie zu tragen.",  Herr fortgesetztes Cannefax, "2006 hat bereits einige kritische positive Änderungen für die Firma erzeugt, der wir ergeben eine drastische Verbesserung in unseren finanziellen Resultaten für dieses Jahr und über glauben.  Spezifisch:  -- eine neue Managementmannschaft ist in Platz eingesetzt worden.  Wir setzen zu rundem es heraus während der Abgleichung des Jahres fort.  -- die Firma hat kanadische Genehmigung durch die zuständige Aufsichtsbehörde für das P60 empfangen.  Dieses folgt Genehmigungen durch die zuständige Aufsichtsbehörde für das Produkt letztes Jahr in den Vereinigten Staaten, in den westeuropäischen Ländern und in einigen Teilen der pazifischen Kante.  Wir schreiben auf dieser globalen high-tech Auge-Obachtgelegenheit schnell gross.  -- Paradigmamedizinisches vor kurzem durchgeführt einer $1.5-millionfinanzierung, die ausreichende Kapital liefert, um globale Verkäufe und Absatzprogramme für unsere Hochseitenrandproduktmappe zu erweitern.  -- die Firma hat sein Lager, Produktion und Büro-Service in einen leistungsfähigeren und kosteneffektiveren Raum vereinigt.  -- internationale Verteilervereinbarungen werden wiederholt und neue Verteiler sind eifrig, medizinische Produkte des Paradigmas in den Ländern, in denen oder begrenzt worden ist, in keiner Produktverteilung in der neuen Vergangenheit zu vermarkten.  -- die Firma erforscht collaborations mit dem Führen der globalen Unternehmen, die Ultraschallforschungs- und -entwicklungs- und -produktionsfähigkeiten haben, zu helfen, neue Produkte zu entwickeln, die global von Paradigm Medical vermarktet werden.  Mehrere dieser Produkte wurden gut bei der AAO-Konferenz empfangen, die im März 2006 gehalten wurde.  -- das medizinische Paradigma wertet zusätzliche Endverbrauchmarktgelegenheiten für seine Ultraschallprodukte in der Augenheilkunde."aus,  "wir legen sogar grösseren Nachdruck auf dem Verringern unserer Betriebskosten und ausreichender Warenbestand Beibehaltens zum Treffen, das erwartet wird, verlangen vier unsere Produkte," Herr addiertes Cannefax.  "die Firma hat ununterbrochene Verbesserungen des Slogans ', ' angenommen und tut genau die -- jeden Aspekt unserer Betriebe ununterbrochen verbessern sowie unsere Produkte.",  Paradigm Medical Industries, Inc., z.Z. entwickelt, stellt her und vermarktet high-tech, eigene Diagnoseausrüstung und verbrauchbare Produkte für die medizinische Industrie.  Die Planungs- und Führungsstäbe der Firma befinden sich bei 2355 Süd1070 West, Salt Lake City, Utah 84119.  Anruf (801) 977-8970 oder besuchen uns an www.paradigm-medical.com.  Dieses Pressekommuniqué enthält Aussagen, die, wenn nicht nachweisbare historische Tatsache, als Vorwärts-schauende Aussagen angesehen werden können, die zukünftige Fälle und Resultate in Bezug auf Paradigma und sein Geschäft voraussagen konnten.  Die Vorhersagen, die in diesen Aussagen dargestellt werden, beziehen Gefahr und Ungewißheiten und dementsprechend tatsächliche Resultate können von den Resultaten erheblich sich unterscheiden mit ein, die in solchen Vorwärts-schauenden Aussagen besprochen werden oder angedeutet sind.  

irgendwann im Mai habe ich gelesen... stimmt das?

bist du hier eigentlich noch dabei?  

The software and hardware modifications designed jointly by the Company and MEDA will be considered the joint intellectual property of the Company and MEDA and may be used, without restriction, unless otherwise previously agreed to, by either party. MEDA also agrees to provide a 12 month warranty on all products that it manufactures for the Company. If defects cannot be corrected at the Company\'s facilities, the products may be returned to MEDA for the purposes of carrying out such repairs as required, and MEDA agrees to return the repaired products to the Company or its designated agent or distributor within ten working days from the date of receiving such products, at no cost to the Company, and MEDA will pay return freight costs.

MEDA further agrees to endeavor to answer any technical inquiries concerning the products it has manufactured. MEDA also agrees to train the Company\'s technical service engineers and designated international distributors as soon as possible after the signing of this Agreement, and as future needs arise and as MEDA can reasonably fit such training into the regular schedules of its employees. MEDA agrees to determine the need for future training on new products as necessary and will offer such training in Tiangin, China. For training conducted outside China, the Company or its designated distributors and/or service centers will be responsible for the traveling, living and hotel expenses for MEDA\'s engineers. Training is at no charge to the Company. The training will also be made available to the Company\'s designated repair agencies in order to provide service and repair on a worldwide basis. Such agencies will be considered authorized repair facilities for the products manufactured by MEDA.

The Agreement shall be effective for three years from date of execution. At the end of the three year term, representatives of the Company and MEDA will confer to determine whether to extend the term of the Agreement. This will have a practical effect of extending the term of the Agreement for an additional 120 days. If mutual agreement for extending the term of the Agreement is not reached within 120 days after the end of the three year term, then the Agreement will be deemed terminated. However, if within the 120 day period, the Company and MEDA mutually agree to extend the term of the Agreement, then thereafter either party may terminate the Agreement by providing 12 months prior written notice to the other party. All outstanding orders at the time of notification will be supplied under the terms of the Agreement, and MEDA will continue to fulfill all orders from the Company until the 12 month notice period has expired.



ITEM 9.01 Financial Statements and Exhibits

(c) Exhibits

moin...bist du hier noch investiert?

wie schätzt du die Perspektive ein?

Vielen Dank im voraus...